

<!-- RR Donnelley Xcelerate Instance Document, based on XBRL 2.1  http://www.edgar-online.com/ -->
<!-- Version:  6.21.3 -->
<!-- Round: 6 -->
<!-- Creation date: 2014-11-09T22:53:21Z -->
<!-- Copyright (c) 2005-2013 R.R. Donnelley & Sons Company All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:galt="http://www.galectintherapeutics.com/20140930" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="galt-20140930.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <galt:MinimumCompanyMarketCapitalization contextRef="eol_PE87402---1410-Q0008_STD_0_20090228_0" unitRef="iso4217_USD" decimals="-6" id="id_5283807_7064D5F2-566D-4B5F-A887-AF393052A712_2001_6">100000000</galt:MinimumCompanyMarketCapitalization>
  <galt:AccruedSeparationAgreement contextRef="eol_PE87402---1410-Q0008_STD_0_20090228_0" unitRef="iso4217_USD" decimals="-5" id="id_5283807_7064D5F2-566D-4B5F-A887-AF393052A712_2001_0">1000000</galt:AccruedSeparationAgreement>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="eol_PE87402---1410-Q0008_STD_0_20090228_0_901032x909105" unitRef="shares" decimals="INF" id="id_5283807_7064D5F2-566D-4B5F-A887-AF393052A712_3001_5">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:EquityMethodInvestments contextRef="eol_PE87402---1410-Q0008_STD_0_20090228_0_901032x909105" unitRef="iso4217_USD" decimals="-5" id="id_5283807_7064D5F2-566D-4B5F-A887-AF393052A712_3001_3">10000000</us-gaap:EquityMethodInvestments>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE87402---1410-Q0008_STD_0_20130131_0_907910x904951" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5283807_8EA5416F-5FE3-440A-B77D-0AFA0EA37D72_2001_1">2.65</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE87402---1410-Q0008_STD_0_20130131_0_907910x904951" unitRef="shares" decimals="0" id="id_5283807_8EA5416F-5FE3-440A-B77D-0AFA0EA37D72_2001_0">5000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE87402---1410-Q0008_STD_0_20130506_0_907909x1011576" unitRef="shares" decimals="INF" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_10001_1">1000000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE87402---1410-Q0008_STD_0_20130506_0_907909x970193" unitRef="shares" decimals="INF" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_11001_0">4000000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <galt:MinimumCompanyMarketCapitalization contextRef="eol_PE87402---1410-Q0008_STD_0_20130801_0" unitRef="iso4217_USD" decimals="-6" id="id_5283807_26CD69E5-E5E2-4CB7-A14C-D227EF863047_1001_0">100000000</galt:MinimumCompanyMarketCapitalization>
  <galt:ExpectedFuturePayments contextRef="eol_PE87402---1410-Q0008_STD_0_20130801_0" unitRef="iso4217_USD" decimals="-6" id="id_5283807_26CD69E5-E5E2-4CB7-A14C-D227EF863047_1001_1">1000000</galt:ExpectedFuturePayments>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE87402---1410-Q0008_STD_0_20141107_0" unitRef="shares" decimals="INF" id="id_5283807_2C45DCBF-49A8-41A1-97CF-A3CE34B6BA22_2_500005">22123583</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="eol_PE87402---1410-Q0008_STD_0_20130630_0" unitRef="shares" decimals="INF" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_9002_5">5000000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE87402---1410-Q0008_STD_0_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_1002_20">9715000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <galt:CommissionsAsPercentageOfGrossOfferingProceeds contextRef="eol_PE87402---1410-Q0008_STD_0_20131025_0_911417x949437" unitRef="pure" decimals="3" id="id_5283807_75821006-2AFC-4758-97F6-89C75BE4705D_1001_1">0.030</galt:CommissionsAsPercentageOfGrossOfferingProceeds>
  <galt:AggregateOfferingPrice contextRef="eol_PE87402---1410-Q0008_STD_0_20131025_0_911417x949437" unitRef="iso4217_USD" decimals="-5" id="id_5283807_75821006-2AFC-4758-97F6-89C75BE4705D_1001_0">30000000</galt:AggregateOfferingPrice>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_48">22123583</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_49">22123583</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_47">50000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5283807_0BF9C0E3-8428-42CA-8CF4-353277F00B0D_3001_6">4.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="pure" decimals="2" id="id_5283807_9E7CBEC3-68D2-42AC-8CCC-98300C46D815_1002_2">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_43">1452500</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="shares" decimals="INF" id="id_5283807_5A834E49-A2A7-430D-BC12-42A792965DCB_1_1">1103474</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_46">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_41">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="shares" decimals="INF" id="id_5283807_68E0613A-F39A-4F10-8478-975554DA92B5_1001_5">5450995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_42">1402500</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="shares" decimals="INF" id="id_5283807_CA2807BB-D346-47C0-98B5-48A8A7F3AC61_3001_6">3328517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:PreferredStockValue contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_40">567000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockLiquidationPreferenceValue contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="0" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_44">1402500</us-gaap:PreferredStockLiquidationPreferenceValue>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_14">1380000</us-gaap:LiabilitiesCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_45">22000</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_16" />
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_11">838000</us-gaap:AccountsPayableCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_51">-114890000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_8A1F28C7-301A-4AF9-9FFB-A80D646D000E_1_4">542000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_52">23217000</us-gaap:StockholdersEquity>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_8A1F28C7-301A-4AF9-9FFB-A80D646D000E_1_3">2000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_53">31319000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_50">137518000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_8A1F28C7-301A-4AF9-9FFB-A80D646D000E_1_0">96000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:Liabilities contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_15">1380000</us-gaap:Liabilities>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_8A1F28C7-301A-4AF9-9FFB-A80D646D000E_1_1">444000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_C0111865-4AEB-4DA7-B559-341DB9F8B5A6_1_0">31201000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_5">1000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_3">90000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:EquityMethodInvestments contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_6">10000</us-gaap:EquityMethodInvestments>
  <us-gaap:Assets contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_8">31319000</us-gaap:Assets>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="0" id="id_5283807_5A834E49-A2A7-430D-BC12-42A792965DCB_1_0">5063000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_7">17000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:AssetsCurrent contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_4">31291000</us-gaap:AssetsCurrent>
  <galt:UndesignatedCapitalStockNoParValue contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_37">0.01</galt:UndesignatedCapitalStockNoParValue>
  <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5283807_31B84037-65AC-4CFF-8EDA-C556D63ABD51_1001_5">3.66</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
  <galt:UndesignatedCapitalStockSharesAuthorized contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_38">20000000</galt:UndesignatedCapitalStockSharesAuthorized>
  <galt:UndesignatedCapitalStockSharesOutstanding contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_39">8001000</galt:UndesignatedCapitalStockSharesOutstanding>
  <galt:UndesignatedCapitalStockValue contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0" unitRef="iso4217_USD" xsi:nil="true" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1_36" />
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x911070" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1001_31">176</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x911070" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1001_30">1000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x911070" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1001_32">176</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x911070" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1001_29">1723000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityLiquidationPreference contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x911070" unitRef="iso4217_USD" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1001_34">1760000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x911070" unitRef="iso4217_USD" decimals="0" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1001_33">4806000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x923281" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2001_19">900000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x923281" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2001_18">900000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x923281" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2001_20">900000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x923281" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2001_17">1727000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityLiquidationPreference contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x923281" unitRef="iso4217_USD" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2001_22">1800000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x923281" unitRef="iso4217_USD" decimals="0" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2001_21">1800000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x985153" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_3001_25">2100000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x985153" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_3001_24">2100000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x985153" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_3001_26">2100000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x985153" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_3001_23">3272000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquityLiquidationPreference contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x985153" unitRef="iso4217_USD" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_3001_28">4200000</us-gaap:TemporaryEquityLiquidationPreference>
  <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests contextRef="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x985153" unitRef="iso4217_USD" decimals="0" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_3001_27">4200000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE87402---1410-Q0008_STD_0_20121231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_2001_19">9364000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_48">18386900</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_49">18386900</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_47">50000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5283807_0BF9C0E3-8428-42CA-8CF4-353277F00B0D_1001_2">4.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_43">1452500</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_46">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_41">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_5283807_68E0613A-F39A-4F10-8478-975554DA92B5_2001_1">6035229</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_42">1402500</us-gaap:PreferredStockSharesIssued>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_5283807_CA2807BB-D346-47C0-98B5-48A8A7F3AC61_1001_2">3348705</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:PreferredStockValue contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_40">587000</us-gaap:PreferredStockValue>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_14">2486000</us-gaap:LiabilitiesCurrent>
  <us-gaap:CommonStockValue contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_45">18000</us-gaap:CommonStockValue>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_16" />
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_11">762000</us-gaap:AccountsPayableCurrent>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_51">-101965000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_8A1F28C7-301A-4AF9-9FFB-A80D646D000E_2_4">1651000</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:StockholdersEquity contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_52">1481000</us-gaap:StockholdersEquity>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_8A1F28C7-301A-4AF9-9FFB-A80D646D000E_2_3">22000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_53">10713000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:AdditionalPaidInCapital contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_50">102841000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccruedProfessionalFeesCurrent contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_8A1F28C7-301A-4AF9-9FFB-A80D646D000E_2_0">103000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:Liabilities contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_15">2486000</us-gaap:Liabilities>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_8A1F28C7-301A-4AF9-9FFB-A80D646D000E_2_1">526000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:DividendsPayableCurrent contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_13">73000</us-gaap:DividendsPayableCurrent>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_2">10489000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_5">3000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_3">198000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:Assets contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_8">10713000</us-gaap:Assets>
  <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_7">23000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
  <us-gaap:AssetsCurrent contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_4">10687000</us-gaap:AssetsCurrent>
  <galt:UndesignatedCapitalStockNoParValue contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_37">0.01</galt:UndesignatedCapitalStockNoParValue>
  <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5283807_31B84037-65AC-4CFF-8EDA-C556D63ABD51_2001_1">3.63</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageExercisePrice>
  <galt:UndesignatedCapitalStockSharesAuthorized contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_38">20000000</galt:UndesignatedCapitalStockSharesAuthorized>
  <galt:UndesignatedCapitalStockSharesOutstanding contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_39">8001000</galt:UndesignatedCapitalStockSharesOutstanding>
  <galt:AccruedSeparationAgreement contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_8A1F28C7-301A-4AF9-9FFB-A80D646D000E_2_2">1000000</galt:AccruedSeparationAgreement>
  <galt:UndesignatedCapitalStockValue contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2_36" />
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0_907909x911070" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1002_31">196</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0_907909x911070" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1002_30">1000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0_907909x911070" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1002_32">196</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0_907909x911070" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_1002_29">1919000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0_907909x923281" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2002_19">900000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0_907909x923281" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2002_18">900000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0_907909x923281" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2002_20">900000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0_907909x923281" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_2002_17">1715000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:TemporaryEquitySharesIssued contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0_907909x985153" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_3002_25">2100000</us-gaap:TemporaryEquitySharesIssued>
  <us-gaap:TemporaryEquitySharesAuthorized contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0_907909x985153" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_3002_24">2100000</us-gaap:TemporaryEquitySharesAuthorized>
  <us-gaap:TemporaryEquitySharesOutstanding contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0_907909x985153" unitRef="shares" decimals="INF" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_3002_26">2100000</us-gaap:TemporaryEquitySharesOutstanding>
  <us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0_907909x985153" unitRef="iso4217_USD" decimals="-3" id="id_5283807_98D0679B-3780-4D74-9565-4F6C0E73DA25_3002_23">3112000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
  <us-gaap:SaleOfStockPricePerShare contextRef="eol_PE87402---1410-Q0008_STD_0_20131231_0_911417x949437" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_5283807_75821006-2AFC-4758-97F6-89C75BE4705D_2002_3">9.02</us-gaap:SaleOfStockPricePerShare>
  <galt:OrganizationalAndSeparationRelatedCharges contextRef="eol_PE87402---1410-Q0008_STD_1_20120502_0" unitRef="iso4217_USD" decimals="-6" id="id_5283807_90A629B4-65A8-4E1E-B9CF-8EA639F9E87D_1_0">1000000</galt:OrganizationalAndSeparationRelatedCharges>
  <galt:ClassOfWarrantOrRightExpirationDateExtensionPeriod contextRef="eol_PE87402---1410-Q0008_STD_1_20130506_0_907909x1011576" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_7001_2">P5Y</galt:ClassOfWarrantOrRightExpirationDateExtensionPeriod>
  <galt:ClassOfWarrantOrRightExpirationDateExtensionPeriod contextRef="eol_PE87402---1410-Q0008_STD_1_20130506_0_907909x970193" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_8001_3">P5Y</galt:ClassOfWarrantOrRightExpirationDateExtensionPeriod>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE87402---1410-Q0008_STD_1_20130816_0" unitRef="shares" decimals="INF" id="id_5283807_90E8EA16-E08D-4326-BDC8-806D8FCAD74D_1_0">500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE87402---1410-Q0008_STD_1_20130816_0" unitRef="iso4217_USD" decimals="0" id="id_5283807_90E8EA16-E08D-4326-BDC8-806D8FCAD74D_1_3">0</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement contextRef="eol_PE87402---1410-Q0008_STD_1_20130816_0" unitRef="iso4217_USD" decimals="0" id="id_5283807_90E8EA16-E08D-4326-BDC8-806D8FCAD74D_1_1">3000000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <galt:ClassOfWarrantOrRightIssuedInPeriod contextRef="eol_PE87402---1410-Q0008_STD_1_20130816_0" unitRef="shares" decimals="INF" id="id_5283807_90E8EA16-E08D-4326-BDC8-806D8FCAD74D_1_2">0</galt:ClassOfWarrantOrRightIssuedInPeriod>
  <galt:MilestonePayments contextRef="eol_PE87402---1410-Q0008_STD_1_20130329_0" unitRef="iso4217_USD" decimals="-5" id="id_5283807_A4729C99-60EB-4B81-935E-55C527C7C344_1_0">1000000</galt:MilestonePayments>
  <galt:LawsuitDamageClaim contextRef="eol_PE87402---1410-Q0008_STD_1_20121012_0" unitRef="iso4217_USD" decimals="-5" id="id_5283807_B86A4726-2ABE-44D5-8EDA-D994F2B25789_1_0">1000000</galt:LawsuitDamageClaim>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5283807_5A834E49-A2A7-430D-BC12-42A792965DCB_3_3">3.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_2_10">-5838000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="pure" decimals="2" id="id_5283807_823444E2-793C-4CE3-978A-00EDE3592510_2_3">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" id="id_5283807_823444E2-793C-4CE3-978A-00EDE3592510_2_1">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="pure" decimals="4" id="id_5283807_823444E2-793C-4CE3-978A-00EDE3592510_2_0">0.0117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="shares" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_4_15">16438000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_4_14">-1.15</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="pure" decimals="2" id="id_5283807_823444E2-793C-4CE3-978A-00EDE3592510_2_2">1.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="shares" decimals="INF" id="id_5283807_A6FA5F42-9E93-4595-A205-08E421EBACF4_2_3">12673806</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_2_7">-126000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_4_4">-9300000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_4_8">11000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_4_13">-18836000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLoss contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_4_9">-9289000</us-gaap:NetIncomeLoss>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_4_6">11000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_2_3">9000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:OperatingExpenses contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_4_3">9300000</us-gaap:OperatingExpenses>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_4_1">4293000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_2_9">-5000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_4_10">613000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_2_18">351000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_2_17">6189000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_2_15">3000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_4_2">5007000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_2_8">45000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_4_11">171000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_782941B8-5D4B-48FE-B5EB-C713AF67DFE6_4_2">3276000</us-gaap:ShareBasedCompensation>
  <galt:AdjustmentForModificationOfWarrants contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_4_12">8763000</galt:AdjustmentForModificationOfWarrants>
  <galt:ProceedsFromStockOptionAndWarrantExercises contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_90E8EA16-E08D-4326-BDC8-806D8FCAD74D_3_4">3189000</galt:ProceedsFromStockOptionAndWarrantExercises>
  <galt:SupplementalDividendsOnConvertiblePreferredStock contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_2_22">694000</galt:SupplementalDividendsOnConvertiblePreferredStock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0_900196x904951" unitRef="shares" decimals="INF" id="id_5283807_A6FA5F42-9E93-4595-A205-08E421EBACF4_1002_0">6548029</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0_900196x907935" unitRef="shares" decimals="INF" id="id_5283807_A6FA5F42-9E93-4595-A205-08E421EBACF4_2002_2">2618772</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0_900196x912734" unitRef="shares" decimals="INF" id="id_5283807_A6FA5F42-9E93-4595-A205-08E421EBACF4_3002_1">3507005</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0_905668x900642" unitRef="iso4217_USD" decimals="-3" id="id_5283807_782941B8-5D4B-48FE-B5EB-C713AF67DFE6_1004_1">2411000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1410-Q0008_STD_273_20130930_0_905668x901079" unitRef="iso4217_USD" decimals="-3" id="id_5283807_782941B8-5D4B-48FE-B5EB-C713AF67DFE6_2004_0">865000</us-gaap:ShareBasedCompensation>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_21BDF171-71E6-4FB9-83EF-16A8D8040485_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Accrued Expenses&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued expenses consist of the following:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;September&amp;#xA0;30,&lt;br /&gt;
 2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;December&amp;#xA0;31,&lt;br /&gt;
 2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;(in thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Legal and accounting fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;103&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;444&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;526&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Severance agreement (Note 8)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,000&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;542&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,651&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_C311A238-0135-45A6-A8F3-EB51C02DE7F6_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Commitments and
 Contingencies&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;Separation Agreement&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In February 2009, the Company entered into a Separation Agreement
 in connection with the resignation of David&amp;#xA0;Platt, Ph.D., the
 Company&amp;#x2019;s former Chief Executive Officer and Chairman of the
 Board of Directors. The Separation Agreement provides for the
 deferral of a $1.0 million separation payment due to Dr.&amp;#xA0;Platt
 upon the earlier occurrence of any of the following milestone
 events: (i)&amp;#xA0;the approval by the Food and Drug Administration
 for a new drug application (&amp;#x201C;NDA&amp;#x201D;) for any drug
 candidate or drug delivery candidate based on the Company&amp;#x2019;s
 GM-CT-01 technology (whether or not such technology is patented),
 in which case Dr.&amp;#xA0;Platt is also entitled to a fully vested
 10-year cashless-exercise stock option to purchase at least 83,334
 shares of common stock at an exercise price not less than the fair
 market value of the common stock determined as of the date of
 grant; (ii)&amp;#xA0;consummation of a transaction with a
 pharmaceutical company expected to result in at least $10.0 million
 of equity investment or $50 million of royalty revenue to the
 Company, in which case Dr.&amp;#xA0;Platt is also entitled to stock
 options on the same terms to purchase at least 50,000 shares of
 common stock; or (iii)&amp;#xA0;the renewed listing of the
 Company&amp;#x2019;s securities on a national securities exchange and
 the achievement of a market capitalization of $100 million. Payment
 upon the events (i)&amp;#xA0;and (iii)&amp;#xA0;may be deferred up to six
 months, and if the Company has insufficient cash at the time of any
 of such events, it may issue Dr.&amp;#xA0;Platt a secured promissory
 note for such amount. If the Company&amp;#xA0;files a voluntary or
 involuntary petition for bankruptcy, whether or not a milestone
 event has occurred, such event shall trigger the obligation to pay
 the $1.0&amp;#xA0;million with the result that Dr.&amp;#xA0;Platt may
 assert a claim for such obligation against the bankruptcy estate.
 During 2011, when it became probable that the Company could be
 relisted on a national securities exchange and eventually reach a
 market capitalization of $100 million, the Company recognized the
 $1.0 million severance payment due to Dr.&amp;#xA0;Platt which was
 included in accrued expenses at December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"&gt;
 &amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;On May&amp;#xA0;2,
 2012, Dr.&amp;#xA0;Platt instituted an arbitration with the American
 Arbitration Association seeking the $1 million payment based on a
 claim that the milestone event in the Separation Agreement
 described in clause (iii)&amp;#xA0;above had occurred. Although the
 Company had listed its common stock on the Nasdaq Capital Markets
 as of March&amp;#xA0;22, 2012, the market capitalization since the
 listing had not reached $100 million when the arbitration was heard
 in October 2012. On November&amp;#xA0;1, 2012, the arbitrator denied
 Dr.&amp;#xA0;Platt&amp;#x2019;s demand in all respects.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On October&amp;#xA0;12, 2012, Dr.&amp;#xA0;Platt commenced a lawsuit under
 the Massachusetts Wage Act against Dr.&amp;#xA0;Traber and
 Mr.&amp;#xA0;McGauley who in their capacities as the Company&amp;#x2019;s
 Chief Executive Officer and the Company&amp;#x2019;s former Chief
 Financial Officer, respectively, can be held individually liable
 under the Wage Act for non-payment of wages. The lawsuit is based
 on the facts and issues raised in the arbitration regarding the
 payment of the $1.0 million separation payment under the Separation
 Agreement, and other unspecified &amp;#x201C;wages&amp;#x201D;. The statute
 provides that a successful claimant may be entitled to multiple
 damages, interest and attorney&amp;#x2019;s fees. On April&amp;#xA0;29,
 2013, the Superior Court allowed Dr.&amp;#xA0;Traber&amp;#x2019;s and
 Mr.&amp;#xA0;McGauley&amp;#x2019;s motion to dismiss. On May&amp;#xA0;28, 2013,
 Dr.&amp;#xA0;Platt filed a Notice of Appeal to appeal the Superior
 Court&amp;#x2019;s order allowing the defendants&amp;#x2019; motion to
 dismiss. On April&amp;#xA0;14, 2014, the Appeals Court denied
 Dr.&amp;#xA0;Platt&amp;#x2019;s appeal of the dismissal in full.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On March&amp;#xA0;29, 2013, the Company instituted arbitration before
 the American Arbitration Association, seeking to rescind or reform
 the Separation Agreement discussed above. The Company claimed that
 Dr.&amp;#xA0;Platt fraudulently induced the Company to enter into the
 Separation Agreement, breached his fiduciary duty to the Company,
 and was unduly enriched from his conduct. Along with removal of the
 $1.0 million milestone payment under the Separation Agreement, the
 Company sought repayment of all separation benefits paid to
 Dr.&amp;#xA0;Platt to date.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 On August&amp;#xA0;1, 2013, the market capitalization of the
 Company&amp;#x2019;s common stock exceeded $100 million and the Company
 received a letter dated October&amp;#xA0;1, 2013, demanding payment of
 the $1 million. As described in the preceding paragraph, the
 Company had previously instituted an arbitration proceeding against
 Dr.&amp;#xA0;Platt seeking to rescind the Separation Agreement,
 including the milestone payment provision, and the Company delayed
 payment pending the outcome of this arbitration. In June 2014, the
 arbitrator issued a judgment in favor of Dr.&amp;#xA0;Platt. In July
 2014, the Company paid the $1 million severance obligation.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Shareholder Class Actions and Derivative Lawsuits&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 8%"&gt;
 Between July&amp;#xA0;30, 2014, and August&amp;#xA0;6, 2014, three putative
 class action complaints were filed in the United States District
 Court for the District of Nevada against the Company and certain of
 its officers and directors on behalf of all persons who purchased
 or otherwise acquired the Company&amp;#x2019;s stock between
 January&amp;#xA0;6, 2014 and July&amp;#xA0;28, 2014.&amp;#xA0;The complaints
 allege that the defendants made false or misleading statements in
 certain press releases and other public statements in violation of
 the federal securities laws.&amp;#xA0;The complaints seek class
 certification, unspecified monetary damages, costs, and
 attorneys&amp;#x2019; fees.&amp;#xA0;The Company disputes the allegations in
 the complaints and intends to vigorously defend against the
 claims.&amp;#xA0;By order entered August&amp;#xA0;22, 2014, the Court
 consolidated the three putative class actions.&amp;#xA0;The
 Court&amp;#x2019;s consolidation order relieves the defendants of any
 obligation to respond to the complaints currently on file and
 provides that defendants may respond to a consolidated amended
 complaint once it is filed by the lead plaintiff(s) to be appointed
 by the Court.&amp;#xA0;Defendants&amp;#x2019; motion to transfer the
 consolidated putative securities class action to the United States
 District Court for the Northern District of Georgia is currently
 fully briefed and pending.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 On August&amp;#xA0;1 and 25, 2014, persons claiming to be Galectin
 shareholders filed putative shareholder derivative complaints in
 the United States District Court for the District of Nevada,
 seeking recovery on behalf of the Company against certain of the
 Company&amp;#x2019;s directors and officers.&amp;#xA0;The putative
 derivative complaints allege that the defendants breached their
 fiduciary duties to the Company&amp;#x2019;s shareholders by causing or
 permitting the Company to make allegedly false and misleading
 public statements concerning the Company&amp;#x2019;s financial results,
 prospects, and internal controls over financial reporting, and by
 allegedly failing to ensure that the Company had adequate internal
 controls over financial reporting.&amp;#xA0;Collectively, the
 complaints also allege that defendants were unjustly enriched,
 aided and abetted breaches of fiduciary duties, abused their
 control of and grossly mismanaged the Company, and violated the
 federal securities laws by allegedly making false or misleading
 statements of material fact in the Company&amp;#x2019;s proxy
 filings.&amp;#xA0;One of the complaints also alleges that certain
 defendants breached their fiduciary duties through allegedly
 improper sales of Galectin stock.&amp;#xA0;The complaints seek
 unspecified monetary damages on behalf of the Company, corporate
 governance reforms, disgorgement of profits, benefits and
 compensation by the defendants, costs, and attorneys&amp;#x2019; and
 experts&amp;#x2019; fees.&amp;#xA0;By order entered September&amp;#xA0;10, 2014,
 the Court consolidated the putative derivative actions.&amp;#xA0;The
 Court&amp;#x2019;s consolidation order relieves the defendants of any
 obligation to respond to the complaints currently on file and
 provides that defendants may respond to a consolidated amended
 complaint once it is filed by the
 plaintiffs.&amp;#xA0;Defendants&amp;#x2019; motion to transfer the
 consolidated putative derivative litigation to the United States
 District Court for the Northern District of Georgia is currently
 fully briefed and pending.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 8%"&gt;
 On August&amp;#xA0;29, 2014, another alleged Galectin shareholder filed
 a putative shareholder derivative complaint in state court in Las
 Vegas, Nevada, seeking recovery on behalf of the Company against
 the same directors and officers who are named as defendants in the
 derivative litigation pending in the United States District Court
 for the District of Nevada. The state court derivative complaint
 alleges claims for breach of fiduciary duties, unjust enrichment,
 and waste of corporate assets, based on allegations that are
 substantially similar to those in the derivative complaints pending
 in the United States District Court for the District of Nevada, and
 seeks unspecified monetary damages on behalf of the Company,
 corporate governance reforms, disgorgement of profits, benefits and
 compensation by the defendants, costs, and attorneys&amp;#x2019; and
 experts&amp;#x2019; fees. The defendants in the state court derivative
 litigation have not yet been required to respond to the allegations
 of the complaint and therefore have not yet done so.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Other Legal Proceedings&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The Company records accruals for such contingencies to the extent
 that the Company concludes that their occurrence is probable and
 the related damages are estimable, except as noted above. There are
 no other pending legal proceedings except as noted above.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_6FAC6872-3E1D-4DFB-BCA7-D33719183A3E_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Loss Per Share&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Basic net loss per common share is computed by dividing the net
 loss available to common stockholders by the weighted average
 number of common shares outstanding during the period. Diluted net
 loss per common share is computed by dividing the net loss
 available to common stockholders by the weighted average number of
 common shares and other potential common shares then outstanding.
 Potential common shares consist of common shares issuable upon the
 assumed exercise of in-the-money stock options and warrants and
 potential common shares related to the conversion of the preferred
 stock. The computation of diluted net loss per share does not
 assume the issuance of common shares that have an anti-dilutive
 effect on net loss per share.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; MARGIN-TOP: 12px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Dilutive shares which could exist pursuant to the exercise of
 outstanding stock instruments and which were not included in the
 calculation because their affect would have been anti-dilutive are
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;September&amp;#xA0;30,&amp;#xA0;2014&lt;br /&gt;
 (shares)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;br /&gt;
 (shares)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants to purchase shares of common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,450,995&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,548,029&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options to purchase shares of common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,328,517&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,507,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Shares of common stock issuable upon conversion of preferred
 stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,527,103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,618,772&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,306,615&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,673,806&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_7FB7656C-C938-4EDE-9395-B0DED41726F3_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of all other options granted is determined using the
 Black-Scholes option-pricing model. The following weighted average
 assumptions were used:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;Nine Months Ended&lt;br /&gt;
 September 30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.58&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected life of the options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.0&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.3&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility of the underlying stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;115&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="shares" decimals="INF" id="id_5283807_68E0613A-F39A-4F10-8478-975554DA92B5_1_4">7500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5283807_0BF9C0E3-8428-42CA-8CF4-353277F00B0D_5001_4">1.91</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <dei:DocumentType contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_112BABAF-945E-4183-BE85-59830F1B6C51_1_0">10-Q</dei:DocumentType>
  <dei:EntityRegistrantName contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_2C45DCBF-49A8-41A1-97CF-A3CE34B6BA22_1_400001">GALECTIN THERAPEUTICS INC</dei:EntityRegistrantName>
  <dei:TradingSymbol contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_2C45DCBF-49A8-41A1-97CF-A3CE34B6BA22_1_400000">GALT</dei:TradingSymbol>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_1020215B-05D6-4AAF-8A95-9C62C4D37171_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 Dilutive shares which could exist pursuant to the exercise of
 outstanding stock instruments and which were not included in the
 calculation because their affect would have been anti-dilutive are
 as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="64%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;September&amp;#xA0;30,&amp;#xA0;2014&lt;br /&gt;
 (shares)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;September&amp;#xA0;30,&amp;#xA0;2013&lt;br /&gt;
 (shares)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Warrants to purchase shares of common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,450,995&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,548,029&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Options to purchase shares of common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,328,517&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,507,005&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Shares of common stock issuable upon conversion of preferred
 stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,527,103&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,618,772&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;11,306,615&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12,673,806&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_B4AF76D5-519A-438A-8B1F-85F25A30DE11_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the stock option activity in the
 Company&amp;#x2019;s equity incentive plans, including non-plan grants
 to Company executives, from December&amp;#xA0;31, 2013
 through&amp;#xA0;September 30, 2014:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Exercise Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,348,705&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;354,823&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.72&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(350,728&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.91&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Options forfeited/cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(24,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, September&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,328,517&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.82&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5283807_5A834E49-A2A7-430D-BC12-42A792965DCB_2_3">10.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <dei:EntityFilerCategory contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_2C45DCBF-49A8-41A1-97CF-A3CE34B6BA22_1_400004">Smaller Reporting Company</dei:EntityFilerCategory>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_5A834E49-A2A7-430D-BC12-42A792965DCB_2_2">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_1_10">-9313000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_7DE5AB2F-426C-4BF0-9E95-4BF18091ABBD_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Following is the stock-based compensation expense related to common
 stock options, common stock, restricted common stock and common
 stock warrants:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;(in thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;224&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;335&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;865&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;653&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,473&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,188&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,411&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;877&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,808&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,271&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="pure" decimals="2" id="id_5283807_823444E2-793C-4CE3-978A-00EDE3592510_1_3">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_823444E2-793C-4CE3-978A-00EDE3592510_1_1">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="shares" decimals="INF" id="id_5283807_CA2807BB-D346-47C0-98B5-48A8A7F3AC61_5001_5">24283</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:BasisOfAccounting contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_57E397D3-631D-4B27-8EFA-41855AB2B0F5_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Basis of Presentation&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Galectin Therapeutics Inc. (the &amp;#x201C;Company&amp;#x201D;) is a
 clinical stage biopharmaceutical company that is applying its
 leadership in galectin science and drug development to create new
 therapies for fibrotic disease and cancer. These drug candidates
 are based on the Company&amp;#x2019;s targeting of galectin proteins
 which are key mediators of biologic and pathologic function. These
 compounds also may have application for drugs to treat other
 diseases and chronic health conditions.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The unaudited condensed consolidated financial statements as
 reported in this Quarterly Report on Form 10-Q reflect all
 adjustments which are, in the opinion of management, necessary to
 present fairly the financial position of the Company as of
 September&amp;#xA0;30, 2014 and the results of its operations for the
 three and nine months ended September&amp;#xA0;30, 2014 and 2013 and
 its cash flows for the nine months ended September&amp;#xA0;30, 2014
 and 2013. All adjustments made to the interim financial statements
 are those of a normal and recurring nature. The Company considers
 events or transactions that occur after the balance sheet date but
 before the financial statements are issued to provide additional
 evidence relative to certain estimates or to identify matters that
 require additional disclosure. Subsequent events have been
 evaluated through the date these financial statements are available
 to be issued. The results for interim periods are not necessarily
 indicative of results which may be expected for any other interim
 period or for the full year. The unaudited condensed consolidated
 financial statements of the Company should be read in conjunction
 with its Annual Report on &lt;font style="white-space:nowrap"&gt;Form&amp;#xA0;10-K&lt;/font&gt; as of and for the year
 ended December&amp;#xA0;31, 2013.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has operated at a loss since its inception and has had
 no significant revenues. The Company anticipates that losses will
 continue for the foreseeable future. At September&amp;#xA0;30, 2014,
 the Company had $31.2 million of unrestricted cash and cash
 equivalents available to fund future operations. The Company
 believes that with the cash on hand at September&amp;#xA0;30, 2014,
 there is sufficient cash to fund currently planned operations
 through mid-2016. The Company&amp;#x2019;s ability to fund operations
 after its current cash resources are exhausted depends on its
 ability to obtain additional financing or achieve profitable
 operations, as to which no assurances can be given. Accordingly,
 based on the forecasts and estimates underlying the Company&amp;#x2019;s
 current operating plan, the financial statements do not currently
 include any adjustments that might be necessary if the Company is
 unable to continue as a going concern.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company was founded in July 2000, was incorporated in the State
 of Nevada in January 2001 under the name
 &amp;#x201C;Pro-Pharmaceuticals, Inc.,&amp;#x201D; and changed its name to
 &amp;#x201C;Galectin Therapeutics Inc.&amp;#x201D; on May&amp;#xA0;26,
 2011.&amp;#xA0;On&amp;#xA0;March&amp;#xA0;23, 2012, the Company began trading
 on The NASDAQ Capital Market under the symbol GALT. Immediately
 prior to March&amp;#xA0;23, 2012, the Company was traded on the
 Over-the Counter Bulletin Board (&amp;#x201C;OTCBB&amp;#x201D;) under the
 symbol GALT.OB.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company is subject to a number of risks similar to those of
 other development-stage companies, including dependence on key
 individuals, uncertainty of product development and generation of
 revenues, dependence on outside sources of capital, risks
 associated with clinical trials of products, dependence on
 third-party collaborators for research operations, need for
 regulatory approval of products, risks associated with protection
 of intellectual property, risks associated with litigation, and
 competition with larger, better-capitalized companies. Successful
 completion of the Company&amp;#x2019;s development program and,
 ultimately, the attainment of profitable operations is dependent
 upon future events, including obtaining adequate financing to
 fulfill its development activities and achieving a level of
 revenues adequate to support the Company&amp;#x2019;s cost structure.
 There are no assurances that the Company will be able to obtain
 additional financing on favorable terms, or at all, or successfully
 market its products.&lt;/p&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company adopted Financial Accounting Standards Board,
 Accounting Standards Update No.&amp;#xA0;2014-10 &amp;#x201C;Development
 Stage Entities (Topic 915)&amp;#x201D; as of June&amp;#xA0;30, 2014. This
 new standard modifies financial statement presentation to eliminate
 the requirement to include inception-to-date information in the
 statements of operations and cash flows, among other
 provisions.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:BasisOfAccounting>
  <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_F6B99C2A-3948-47BD-B3D5-E846525633DE_1_0">&lt;div&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued expenses consist of the following:&lt;/p&gt;
 &lt;p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;September&amp;#xA0;30,&lt;br /&gt;
 2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;December&amp;#xA0;31,&lt;br /&gt;
 2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;(in thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Legal and accounting fees&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;96&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;103&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Accrued compensation&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;444&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;526&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Severance agreement (Note 8)&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,000&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:1.00px solid #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;542&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="font-size:8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,651&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="border-top:3.00px double #000000"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="shares" decimals="INF" id="id_5283807_CA2807BB-D346-47C0-98B5-48A8A7F3AC61_5001_3">354823</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="shares" xsi:nil="true" id="id_5283807_68E0613A-F39A-4F10-8478-975554DA92B5_1_2" />
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="pure" decimals="4" id="id_5283807_823444E2-793C-4CE3-978A-00EDE3592510_1_0">0.0158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="shares" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_3_15">21732000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <dei:DocumentPeriodEndDate contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_112BABAF-945E-4183-BE85-59830F1B6C51_1_2">2014-09-30</dei:DocumentPeriodEndDate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="shares" decimals="INF" id="id_5283807_68E0613A-F39A-4F10-8478-975554DA92B5_1_3">576734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5283807_0BF9C0E3-8428-42CA-8CF4-353277F00B0D_5001_5">3.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_AE5B3429-89FE-4397-8CB6-E9C756693931_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"&gt;
 &lt;i&gt;At Market Issuance of Common Stock&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On October&amp;#xA0;25, 2013, the Company entered into an At Market
 Issuance Sales Agreement (the &amp;#x201C;At Market Agreement&amp;#x201D;)
 with a sales agent under which the Company may issue and sell
 shares of its common stock having an aggregate offering price of up
 to $30.0&amp;#xA0;million from time to time through the sales agent.
 Sales of the Company&amp;#x2019;s common stock through the sales agent,
 if any, will be made by any method that is deemed an &amp;#x201C;at the
 market&amp;#x201D; offering as defined by the U.S. Securities and
 Exchange Commission. The Company will pay to the sales agent a
 commission rate equal to 3.0% of the gross proceeds from the sale
 of any shares of common stock sold through the sales agent under
 the At Market Agreement. As of December&amp;#xA0;31, 2013, the Company
 had issued 99,942 shares of its common stock through its At Market
 issuance program at an average price of $9.02 per share resulting
 in gross proceeds of approximately $944,000. The Company incurred
 one time, initial legal and accounting costs of approximately
 $82,000 and commissions of $29,000 resulting in net proceeds of
 $833,000 as of December&amp;#xA0;31, 2013. During the nine months ended
 September 30, 2014, the Company issued 2,674,500 shares of common
 stock for net proceeds of approximately $28,238,000.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;2013 Private Placement of Common Stock&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On August 16, 2013, the Company issued 500,000 unregistered shares
 of its common stock for proceeds of $3,000,000 to a single investor
 pursuant to a private placement. There were no warrants or
 placement fees associated with this transaction.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Other Issuances of Common Stock&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 For the nine-month periods ended September 30, 2014 and 2013 the
 Company issued shares of common stock in exchange for cash proceeds
 of $2,187,000 and $3,189,000, respectively, related to the exercise
 of stock options and warrants.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <dei:AmendmentFlag contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_112BABAF-945E-4183-BE85-59830F1B6C51_1_1">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_2C45DCBF-49A8-41A1-97CF-A3CE34B6BA22_1_400003">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_112BABAF-945E-4183-BE85-59830F1B6C51_1_3">2014</dei:DocumentFiscalYearFocus>
  <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_D4794F96-F4EF-4BC2-AADF-8B6B8020B038_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Galectin Sciences LLC&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In January 2014, we created Galectin Sciences, LLC (the
 &amp;#x201C;LLC&amp;#x201D; or &amp;#x201C;Investee&amp;#x201D;), a collaborative joint
 venture co-owned by SBH Sciences, Inc. (&amp;#x201C;SBH&amp;#x201D;), to
 research and develop small organic molecule inhibitors of
 galectin-3 for oral administration. The LLC was initially
 capitalized with a $400,000 cash investment to fund future research
 and development activities, which was provided by the Company, and
 specific in-process research and development
 (&amp;#x201C;IPR&amp;amp;D&amp;#x201D;) contributed by SBH.&amp;#xA0;The estimated
 fair value of the IPR&amp;amp;D contributed by SBH, on the date of
 contribution, was $400,000.&amp;#xA0;Both the Company and SBH have a
 50% equity ownership interest in the LLC, with neither party having
 control over the LLC.&amp;#xA0;Accordingly, the Company has accounted
 for its investment in the LLC using the equity method of
 accounting.&amp;#xA0;Under the equity method of accounting, the
 Company&amp;#x2019;s investment was initially recorded at cost with
 subsequent adjustments to the carrying value to recognize
 additional investments in or distributions from the Investee, as
 wells the Company&amp;#x2019;s share of the Investee&amp;#x2019;s earnings,
 losses and/or changes in capital. The estimated fair value of the
 IPR&amp;amp;D contributed to the LLC was immediately expensed upon
 contribution as there was no alternative future use available at
 the point of contribution.&amp;#xA0;The Company&amp;#x2019;s portion of the
 LLC&amp;#x2019;s net loss for the nine month period ending
 September&amp;#xA0;30, 2014 was $390,000, which includes
 the&amp;#xA0;Company&amp;#x2019;s proportionate share of the non-cash charge
 associated with the contributed IPR&amp;amp;D of $200,000.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5283807_0BF9C0E3-8428-42CA-8CF4-353277F00B0D_5001_3">12.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_C158CE22-5338-41F4-BEB2-D8BD2BDDC2C1_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Subsequent Events&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has evaluated all events or transactions that occurred
 through the date on which the financial statements were issued,
 with no items noted for disclosure or recording in the consolidated
 financial statements as of September&amp;#xA0;30, 2014.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <dei:EntityCentralIndexKey contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_2C45DCBF-49A8-41A1-97CF-A3CE34B6BA22_1_400002">0001133416</dei:EntityCentralIndexKey>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_11A3C791-93D5-4A26-AD3E-17AC247AC6DB_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 Following is the stock-based compensation expense related to common
 stock options, common stock, restricted common stock and common
 stock warrants:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="73%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;Nine&amp;#xA0;Months&amp;#xA0;Ended&lt;br /&gt;
 September&amp;#xA0;30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;(in thousands)&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;224&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;335&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,083&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;865&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;653&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,473&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,188&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,411&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Total stock-based compensation expense&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;877&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,808&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,271&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,276&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the stock option activity in the
 Company&amp;#x2019;s equity incentive plans, including non-plan grants
 to Company executives, from December&amp;#xA0;31, 2013
 through&amp;#xA0;September 30, 2014:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Exercise Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,348,705&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.70&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;354,823&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;12.72&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(350,728&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.91&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Options forfeited/cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(24,283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, September&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,328,517&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4.82&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 As of September&amp;#xA0;30, 2014, there was $5,063,000 of unrecognized
 compensation related to 1,103,474 unvested options, which is
 expected to be recognized over a weighted&amp;#x2013;average period of
 approximately 2 years. The weighted-average grant date fair value
 for options granted during the nine months ended September&amp;#xA0;30,
 2014 and 2013 was $10.75 and $3.17, respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 The fair value of all other options granted is determined using the
 Black-Scholes option-pricing model. The following weighted average
 assumptions were used:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="4%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;Nine Months Ended&lt;br /&gt;
 September 30,&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2014&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;2013&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Risk-free interest rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.58&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1.17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected life of the options&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6.0&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5.3&amp;#xA0;years&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected volatility of the underlying stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;114&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;115&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Expected dividend rate&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;%&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"&gt;
 In January 2014, the Company entered into an agreement with a
 consultant that provided for the grant of common stock as part of
 the compensation to the consultant. During the three months ended
 September 30, 2014, the Company issued 3,873 shares of its common
 stock valued at $50,000 under the agreement. During the nine months
 ended September 30, 2014, the Company issued 8,966 shares of its
 common stock valued at $100,000 under the agreement. This agreement
 ended in October 2014.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_3_14">-0.60</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:FairValueDisclosuresTextBlock contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_F2DA3B80-5E45-48D0-8E70-84AEBA496987_1_0">&lt;div&gt;
 &lt;table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"&gt;
 &lt;tr&gt;
 &lt;td width="4%" valign="top" align="left"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/td&gt;
 &lt;td align="left" valign="top"&gt;&lt;b&gt;Fair Value of Financial
 Instruments&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 The Company has certain financial assets and liabilities recorded
 at fair value. Fair values determined by Level 1 inputs utilize
 observable data such as quoted prices in active markets. Fair
 values determined by Level 2 inputs utilize data points other than
 quoted prices in active markets that are observable either directly
 or indirectly. Fair values determined by Level 3 inputs utilize
 unobservable data points in which there is little or no market
 data, which require the reporting entity to develop its own
 assumptions. The carrying amounts reflected in the consolidated
 balance sheets for cash and cash equivalents, accounts payable and
 accrued expenses approximates their carrying value due to their
 short-term nature. There were no level 2 or level 3 assets held at
 fair value at September&amp;#xA0;30, 2014 or December&amp;#xA0;31,
 2013.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_35DBB6D3-9DCA-4F23-86D6-C485704E8652_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the common stock warrant activity
 from December&amp;#xA0;31, 2013 through September&amp;#xA0;30, 2014:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Exercise Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,035,229&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.63&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;576,734&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Forfeited/cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, September&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,450,995&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.66&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="pure" decimals="2" id="id_5283807_823444E2-793C-4CE3-978A-00EDE3592510_1_2">1.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_112BABAF-945E-4183-BE85-59830F1B6C51_1_4">Q3</dei:DocumentFiscalPeriodFocus>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="shares" decimals="INF" id="id_5283807_A6FA5F42-9E93-4595-A205-08E421EBACF4_1_3">11306615</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="shares" decimals="INF" id="id_5283807_CA2807BB-D346-47C0-98B5-48A8A7F3AC61_5001_4">350728</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_1_7">-108000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_3_4">-11696000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_3_8">-361000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:PaymentsToAcquireEquityMethodInvestments contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_1_12">400000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_3_13">-12992000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLoss contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_3_9">-12057000</us-gaap:NetIncomeLoss>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_3_6">29000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_9E7CBEC3-68D2-42AC-8CCC-98300C46D815_2_3">-390000</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:DepreciationDepletionAndAmortization contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_1_3">8000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:OperatingExpenses contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_3_3">11696000</us-gaap:OperatingExpenses>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_3_1">6345000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_3_10">763000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_1_18">20712000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_1_17">30425000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_1_15">28238000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ResearchAndDevelopmentInProcess contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="0" id="id_5283807_9E7CBEC3-68D2-42AC-8CCC-98300C46D815_2_4">200000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_1_13">-400000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_3_2">5351000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_1_8">-1033000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_3_11">172000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_782941B8-5D4B-48FE-B5EB-C713AF67DFE6_3_2">3271000</us-gaap:ShareBasedCompensation>
  <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5283807_31B84037-65AC-4CFF-8EDA-C556D63ABD51_1_3">3.11</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD_per_shares" xsi:nil="true" id="id_5283807_31B84037-65AC-4CFF-8EDA-C556D63ABD51_1_2" />
  <galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5283807_31B84037-65AC-4CFF-8EDA-C556D63ABD51_1_4">15.00</galt:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <galt:StockWarrantsTextBlock contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" id="id_5283807_98DF67C9-FEF9-4BE7-AB66-FBE923B9A405_1_0">&lt;div&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="100%" border="0"&gt;
 &lt;tr&gt;
 &lt;td valign="top" width="4%" align="left"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="top" align="left"&gt;&lt;b&gt;Common Stock Warrants&lt;/b&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the common stock warrant activity
 from December&amp;#xA0;31, 2013 through September&amp;#xA0;30, 2014:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="8%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Shares&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;Weighted&amp;#xA0;Average&lt;br /&gt;
 Exercise Price&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, December&amp;#xA0;31, 2013&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,035,229&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.63&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Granted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Exercised&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;576,734&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 3em; TEXT-INDENT: -1em"&gt;
 Forfeited/cancelled&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(7,500&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;15.00&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 1px solid"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; TEXT-INDENT: -1em"&gt;
 Outstanding, September&amp;#xA0;30, 2014&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;5,450,995&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;font style="FONT-SIZE: 8pt"&gt;&amp;#xA0;&lt;/font&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3.66&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="BORDER-TOP: #000000 3px double"&gt;&amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Consultant Warrants&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 In January 2013, the Company entered into an agreement with a
 consultant that provided for the grant of warrants for the purchase
 of 5,000 shares of common stock at an exercise price of $2.65 per
 share. The following assumptions were used to value the warrants:
 an expected life of 3 years, volatility of 87%, risk free interest
 rate of 0.42% and zero dividends. The Company recognized an expense
 of $7,000 related to these warrants at the time of grant as they
 were vested upon issuance.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"&gt;
 &lt;i&gt;Warrants Modification&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 On May&amp;#xA0;6, 2013, the Company modified the terms of the
 Class&amp;#xA0;A-2 and Class B warrants that were originally issued to
 the 10X Fund with the Series B Preferred Stock offering. The Class
 B warrants were modified to allow for the cashless exercise of all
 4,000,000 outstanding Class B warrants. Previously, only half of
 the Class B warrants allowed for cashless exercise. The
 Class&amp;#xA0;A-2 warrants for the purchase of 1,000,000 shares of
 common and all of the Class B warrants had their exercisable life
 extended by an additional five years. In exchange for these
 modifications, the 10X Fund agreed to a future amendment of the
 Company&amp;#x2019;s Series B certificate of designation to remove the
 redemption provision such that the Series B Preferred Stock will no
 longer be redeemable, if and when the Company will no longer be
 required to issue Dr.&amp;#xA0;Platt a promissory note as may currently
 be required under the separation agreement (see Note
 8).&amp;#xA0;Should the Company amend their Series B certificate of
 designation in the future as described above, the Company will be
 required at that time to evaluate whether such amendment is to be
 accounted for as a modification or an extinguishment of the
 Company&amp;#x2019;s Series B Preferred Stock.&amp;#xA0;The Company has
 accounted for the modified terms of the Class&amp;#xA0;A-2 and Class B
 warrants pursuant to ASC 718, Stock Compensation, whereby the
 Company has recognized a charge for the change in fair value of the
 warrants immediately before and immediately after the
 modification.&amp;#xA0;The Company recognized a charge of $8,763,000
 related to the extension of the 5,000,000 warrants in the quarter
 ended June&amp;#xA0;30, 2013. The following assumptions were used to
 value the extension of the warrants immediately before and
 immediately after the modification: a) immediately before the
 modification&amp;#x2014;an expected life range of 0.77 to 2.01 years,
 volatility range of 77% to 96%, risk free interest rate range of
 0.11% to 0.22% and zero dividends and; b) immediately following the
 modification&amp;#x2014;an expected life range of 5.78 to 7.02 years,
 volatility range of 113% to 122%, risk free interest rate range of
 0.74% to 1.19% and zero dividends.&lt;/p&gt;
 &lt;/div&gt;</galt:StockWarrantsTextBlock>
  <galt:ProceedsFromStockOptionAndWarrantExercises contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_90E8EA16-E08D-4326-BDC8-806D8FCAD74D_2_4">2187000</galt:ProceedsFromStockOptionAndWarrantExercises>
  <galt:SupplementalDividendsOnConvertiblePreferredStock contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_00BB94CB-7CF2-4478-87B4-90D569D87CA4_1_22">766000</galt:SupplementalDividendsOnConvertiblePreferredStock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0_900196x904951" unitRef="shares" decimals="INF" id="id_5283807_A6FA5F42-9E93-4595-A205-08E421EBACF4_1001_0">5450995</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0_900196x907935" unitRef="shares" decimals="INF" id="id_5283807_A6FA5F42-9E93-4595-A205-08E421EBACF4_2001_2">2527103</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0_900196x912734" unitRef="shares" decimals="INF" id="id_5283807_A6FA5F42-9E93-4595-A205-08E421EBACF4_3001_1">3328517</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <galt:AgreementTerminationMonthAndYear contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0_904892x921908" id="id_5283807_B92F4A6A-0AAF-49F5-880F-716641B541EC_1002_2">2014-10</galt:AgreementTerminationMonthAndYear>
  <galt:FairMarketValueOfShares contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0_904892x921908" unitRef="iso4217_USD" decimals="0" id="id_5283807_B92F4A6A-0AAF-49F5-880F-716641B541EC_1002_1">100000</galt:FairMarketValueOfShares>
  <galt:CommonStockOptionsGrantedShares contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0_904892x921908" unitRef="shares" decimals="INF" id="id_5283807_B92F4A6A-0AAF-49F5-880F-716641B541EC_1002_0">8966</galt:CommonStockOptionsGrantedShares>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0_905668x900642" unitRef="iso4217_USD" decimals="-3" id="id_5283807_782941B8-5D4B-48FE-B5EB-C713AF67DFE6_1003_1">2188000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0_905668x901079" unitRef="iso4217_USD" decimals="-3" id="id_5283807_782941B8-5D4B-48FE-B5EB-C713AF67DFE6_2003_0">1083000</us-gaap:ShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0_911417x949437" unitRef="shares" decimals="INF" id="id_5283807_75821006-2AFC-4758-97F6-89C75BE4705D_1003_8">2674500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE87402---1410-Q0008_STD_273_20140930_0_911417x949437" unitRef="iso4217_USD" decimals="0" id="id_5283807_75821006-2AFC-4758-97F6-89C75BE4705D_1003_9">28238000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="eol_PE87402---1410-Q0008_STD_28_20090228_0" unitRef="shares" decimals="INF" id="id_5283807_7064D5F2-566D-4B5F-A887-AF393052A712_1_2">83334</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:RoyaltyRevenue contextRef="eol_PE87402---1410-Q0008_STD_28_20090228_0" unitRef="iso4217_USD" decimals="-6" id="id_5283807_7064D5F2-566D-4B5F-A887-AF393052A712_1_4">50000000</us-gaap:RoyaltyRevenue>
  <galt:SeverancePaymentPeriod contextRef="eol_PE87402---1410-Q0008_STD_28_20090228_0" id="id_5283807_7064D5F2-566D-4B5F-A887-AF393052A712_1_7">P6M</galt:SeverancePaymentPeriod>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="eol_PE87402---1410-Q0008_STD_28_20090228_0_901032x909105" id="id_5283807_7064D5F2-566D-4B5F-A887-AF393052A712_1001_1">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired contextRef="eol_PE87402---1410-Q0008_STD_31_20140131_0" unitRef="iso4217_USD" decimals="0" id="id_5283807_9E7CBEC3-68D2-42AC-8CCC-98300C46D815_1_1">400000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFairValueAcquired>
  <galt:InitialCapitalContribution contextRef="eol_PE87402---1410-Q0008_STD_31_20140131_0" unitRef="iso4217_USD" decimals="0" id="id_5283807_9E7CBEC3-68D2-42AC-8CCC-98300C46D815_1_0">400000</galt:InitialCapitalContribution>
  <us-gaap:SeveranceCosts1 contextRef="eol_PE87402---1410-Q0008_STD_31_20140731_0" unitRef="iso4217_USD" decimals="-6" id="id_5283807_26CD69E5-E5E2-4CB7-A14C-D227EF863047_2_2">1000000</us-gaap:SeveranceCosts1>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE87402---1410-Q0008_STD_365_20131231_0_911417x949437" unitRef="shares" decimals="INF" id="id_5283807_75821006-2AFC-4758-97F6-89C75BE4705D_1002_2">99942</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:PaymentsForCommissions contextRef="eol_PE87402---1410-Q0008_STD_365_20131231_0_911417x949437" unitRef="iso4217_USD" decimals="0" id="id_5283807_75821006-2AFC-4758-97F6-89C75BE4705D_1002_6">29000</us-gaap:PaymentsForCommissions>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE87402---1410-Q0008_STD_365_20131231_0_911417x949437" unitRef="iso4217_USD" decimals="0" id="id_5283807_75821006-2AFC-4758-97F6-89C75BE4705D_1002_7">833000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <galt:GrossProceedsFromIssuanceOfCommonStock contextRef="eol_PE87402---1410-Q0008_STD_365_20131231_0_911417x949437" unitRef="iso4217_USD" decimals="0" id="id_5283807_75821006-2AFC-4758-97F6-89C75BE4705D_1002_4">944000</galt:GrossProceedsFromIssuanceOfCommonStock>
  <galt:LegalAccountingUnderwritingFee contextRef="eol_PE87402---1410-Q0008_STD_365_20131231_0_911417x949437" unitRef="iso4217_USD" decimals="0" id="id_5283807_75821006-2AFC-4758-97F6-89C75BE4705D_1002_5">82000</galt:LegalAccountingUnderwritingFee>
  <us-gaap:LossContingencyNewClaimsFiledNumber contextRef="eol_PE87402---1410-Q0008_STD_6_20140806_0" unitRef="LegalMatter" decimals="INF" id="id_5283807_19BF3762-0A8E-4EAD-9C74-1EC3BB8BD07F_1_0">3</us-gaap:LossContingencyNewClaimsFiledNumber>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE87402---1410-Q0008_STD_92_20130930_0" unitRef="shares" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_2_15">16988000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE87402---1410-Q0008_STD_92_20130930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_2_14">-0.22</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE87402---1410-Q0008_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_2_4">-3545000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE87402---1410-Q0008_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_2_8">3000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE87402---1410-Q0008_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_2_13">-3723000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLoss contextRef="eol_PE87402---1410-Q0008_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_2_9">-3542000</us-gaap:NetIncomeLoss>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE87402---1410-Q0008_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_2_6">3000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:OperatingExpenses contextRef="eol_PE87402---1410-Q0008_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_2_3">3545000</us-gaap:OperatingExpenses>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE87402---1410-Q0008_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_2_1">1192000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE87402---1410-Q0008_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_2_10">123000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE87402---1410-Q0008_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_2_2">2353000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="eol_PE87402---1410-Q0008_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_2_11">58000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1410-Q0008_STD_92_20130930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_782941B8-5D4B-48FE-B5EB-C713AF67DFE6_2_2">1808000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1410-Q0008_STD_92_20130930_0_905668x900642" unitRef="iso4217_USD" decimals="-3" id="id_5283807_782941B8-5D4B-48FE-B5EB-C713AF67DFE6_1002_1">1473000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1410-Q0008_STD_92_20130930_0_905668x901079" unitRef="iso4217_USD" decimals="-3" id="id_5283807_782941B8-5D4B-48FE-B5EB-C713AF67DFE6_2002_0">335000</us-gaap:ShareBasedCompensation>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE87402---1410-Q0008_STD_92_20140930_0" unitRef="shares" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_1_15">22051000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE87402---1410-Q0008_STD_92_20140930_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_1_14">-0.17</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE87402---1410-Q0008_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_1_4">-3477000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE87402---1410-Q0008_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_1_8">-41000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE87402---1410-Q0008_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_1_13">-3853000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLoss contextRef="eol_PE87402---1410-Q0008_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_1_9">-3518000</us-gaap:NetIncomeLoss>
  <us-gaap:InvestmentIncomeInterest contextRef="eol_PE87402---1410-Q0008_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_1_6">12000</us-gaap:InvestmentIncomeInterest>
  <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="eol_PE87402---1410-Q0008_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_1_7">-53000</us-gaap:IncomeLossFromEquityMethodInvestments>
  <us-gaap:OperatingExpenses contextRef="eol_PE87402---1410-Q0008_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_1_3">3477000</us-gaap:OperatingExpenses>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE87402---1410-Q0008_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_1_1">1979000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact contextRef="eol_PE87402---1410-Q0008_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_1_10">278000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE87402---1410-Q0008_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_1_2">1498000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="eol_PE87402---1410-Q0008_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_6085404E-3023-4A54-9CA2-39954C4F139C_1_11">57000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1410-Q0008_STD_92_20140930_0" unitRef="iso4217_USD" decimals="-3" id="id_5283807_782941B8-5D4B-48FE-B5EB-C713AF67DFE6_1_2">877000</us-gaap:ShareBasedCompensation>
  <galt:FairMarketValueOfShares contextRef="eol_PE87402---1410-Q0008_STD_92_20140930_0_904892x921908" unitRef="iso4217_USD" decimals="0" id="id_5283807_B92F4A6A-0AAF-49F5-880F-716641B541EC_1001_1">50000</galt:FairMarketValueOfShares>
  <galt:CommonStockOptionsGrantedShares contextRef="eol_PE87402---1410-Q0008_STD_92_20140930_0_904892x921908" unitRef="shares" decimals="INF" id="id_5283807_B92F4A6A-0AAF-49F5-880F-716641B541EC_1001_0">3873</galt:CommonStockOptionsGrantedShares>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1410-Q0008_STD_92_20140930_0_905668x900642" unitRef="iso4217_USD" decimals="-3" id="id_5283807_782941B8-5D4B-48FE-B5EB-C713AF67DFE6_1001_1">653000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1410-Q0008_STD_92_20140930_0_905668x901079" unitRef="iso4217_USD" decimals="-3" id="id_5283807_782941B8-5D4B-48FE-B5EB-C713AF67DFE6_2001_0">224000</us-gaap:ShareBasedCompensation>
  <galt:WarrantExpense contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0" unitRef="iso4217_USD" decimals="0" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_2_4">8763000</galt:WarrantExpense>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_901032x907457_904843x1027896" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_1002_14">P7Y7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_901032x907457_904843x1067104" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_2002_7">P2Y4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_901032x909105_904843x1027896" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_3002_13">P5Y9M11D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_901032x909105_904843x1067104" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_4002_6">P9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_904843x1027896" unitRef="pure" decimals="2" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_5002_15">1.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_904843x1027896" unitRef="pure" decimals="4" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_5002_17">0.0074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_904843x1027896" unitRef="pure" decimals="2" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_5002_16">1.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_904843x1027896" unitRef="pure" decimals="4" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_5002_18">0.0119</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_904843x1027896" unitRef="iso4217_USD" decimals="0" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_5002_19">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_904843x1067104" unitRef="pure" decimals="2" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_6002_8">0.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_904843x1067104" unitRef="pure" decimals="4" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_6002_10">0.0011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_904843x1067104" unitRef="pure" decimals="2" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_6002_9">0.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_904843x1067104" unitRef="pure" decimals="4" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_6002_11">0.0022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_904843x1067104" unitRef="iso4217_USD" decimals="0" id="id_5283807_777894F5-74E4-4040-A08E-1B62721E08BF_6002_12">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_907910x904951" unitRef="pure" decimals="2" id="id_5283807_8EA5416F-5FE3-440A-B77D-0AFA0EA37D72_1002_5">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_907910x904951" id="id_5283807_8EA5416F-5FE3-440A-B77D-0AFA0EA37D72_1002_2">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_907910x904951" unitRef="pure" decimals="4" id="id_5283807_8EA5416F-5FE3-440A-B77D-0AFA0EA37D72_1002_4">0.0042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_907910x904951" unitRef="pure" decimals="2" id="id_5283807_8EA5416F-5FE3-440A-B77D-0AFA0EA37D72_1002_3">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE87402---1410-Q0008_STD_93_20130630_0_907910x904951" unitRef="iso4217_USD" decimals="0" id="id_5283807_8EA5416F-5FE3-440A-B77D-0AFA0EA37D72_1002_6">7000</us-gaap:ShareBasedCompensation>
  <context id="eol_PE87402---1410-Q0008_STD_93_20130630_0_907910x904951">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-03-30</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_93_20130630_0_904843x1067104">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">galt:BeforeModificationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-03-30</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_93_20130630_0_904843x1027896">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">galt:AfterModificationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-03-30</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_93_20130630_0_901032x909105_904843x1067104">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">galt:BeforeModificationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-03-30</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_93_20130630_0_901032x909105_904843x1027896">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">galt:AfterModificationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-03-30</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_93_20130630_0_901032x907457_904843x1067104">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">galt:BeforeModificationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-03-30</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_93_20130630_0_901032x907457_904843x1027896">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">galt:AfterModificationMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-03-30</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_93_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2013-03-30</startDate>
      <endDate>2013-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_92_20140930_0_905668x901079">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_92_20140930_0_905668x900642">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_92_20140930_0_904892x921908">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">galt:ConsultantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_92_20140930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_92_20130930_0_905668x901079">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_92_20130930_0_905668x900642">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_92_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2013-07-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_6_20140806_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2014-08-01</startDate>
      <endDate>2014-08-06</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_365_20131231_0_911417x949437">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:MarketSaleAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_31_20140731_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2014-07-01</startDate>
      <endDate>2014-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_31_20140131_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_28_20090228_0_901032x909105">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2009-02-01</startDate>
      <endDate>2009-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_28_20090228_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2009-02-01</startDate>
      <endDate>2009-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_273_20140930_0_911417x949437">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:MarketSaleAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_273_20140930_0_905668x901079">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_273_20140930_0_905668x900642">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_273_20140930_0_904892x921908">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">galt:ConsultantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_273_20140930_0_900196x912734">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_273_20140930_0_900196x907935">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_273_20140930_0_900196x904951">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_273_20140930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_273_20130930_0_905668x901079">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_273_20130930_0_905668x900642">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_273_20130930_0_900196x912734">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_273_20130930_0_900196x907935">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_273_20130930_0_900196x904951">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_273_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2013-01-01</startDate>
      <endDate>2013-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_1_20121012_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2012-10-12</startDate>
      <endDate>2012-10-12</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_1_20130329_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2013-03-29</startDate>
      <endDate>2013-03-29</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_1_20130816_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2013-08-16</startDate>
      <endDate>2013-08-16</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_1_20130506_0_907909x970193">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:ClassBWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-05-06</startDate>
      <endDate>2013-05-06</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_1_20130506_0_907909x1011576">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:ClassATwoWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2013-05-06</startDate>
      <endDate>2013-05-06</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_1_20120502_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <startDate>2012-05-02</startDate>
      <endDate>2012-05-02</endDate>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20131231_0_911417x949437">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:MarketSaleAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20131231_0_907909x985153">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBTwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20131231_0_907909x923281">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBOnePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20131231_0_907909x911070">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20131231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2013-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20121231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2012-12-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x985153">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBTwoPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x923281">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:SeriesBOnePreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20140930_0_907909x911070">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20140930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2014-09-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20131025_0_911417x949437">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">galt:MarketSaleAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-10-25</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20130930_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2013-09-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20130630_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2013-06-30</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20141107_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2014-11-07</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20130801_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2013-08-01</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20130506_0_907909x970193">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:ClassBWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-05-06</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20130506_0_907909x1011576">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">galt:ClassATwoWarrantsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-05-06</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20130131_0_907910x904951">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2013-01-31</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20090228_0_901032x909105">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2009-02-28</instant>
    </period>
  </context>
  <context id="eol_PE87402---1410-Q0008_STD_0_20090228_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001133416</identifier>
    </entity>
    <period>
      <instant>2009-02-28</instant>
    </period>
  </context>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="LegalMatter">
    <measure>galt:LegalMatter</measure>
  </unit>
</xbrl>